Navigation Links
Strategy discovered to activate genes that suppress tumors and inhibit cancer

A team of scientists has developed a promising new strategy for "reactivating" genes that cause cancer tumors to shrink and die. The researchers hope that their discovery will aid in the development of an innovative anti-cancer drug that effectively targets unhealthy, cancerous tissue without damaging healthy, non-cancerous tissue and vital organs. The research will be published in the Journal of Biological Chemistry.

The team, led by Yanming Wang, a Penn State University associate professor of biochemistry and molecular biology, and Gong Chen, a Penn State assistant professor of chemistry, developed the new strategy after years of earlier research on a gene called PAD4 (peptidylarginine deiminase 4), which produces the PAD4 enzyme. Previous research by Wang and other scientists revealed that the PAD4 enzyme plays an important role in protecting the body from infection. The scientists compared normal mice with a functioning PAD4 gene to other mice that had a defective a PAD4 gene. When infected with bacteria, cells from the normal mice attacked and killed about 30 percent of the harmful bacteria, while cells from the defective mice battled a mere 10 percent. The researchers discovered that cells with a functioning PAD4 enzyme are able to build around themselves a protective, bacteria-killing web that Wang and his colleagues dubbed a NET (neutrophil extracellular trap). This NET is especially effective at fighting off flesh-eating bacteria.

Now, in their new study, Wang and his collaborators have focused on the less-desirable effects of the same PAD4 gene. While PAD4 is clearly a critical part of the body's defense strategy, the gene's over-expression may be linked to autoimmune diseases such as rheumatoid arthritis and multiple sclerosis. One situation in which the PAD4 enzyme is markedly increased is in patients with certain cancers, such as breast, lung, and bone cancers. "We know that the PAD4 gene acts to silence tumor-suppressor genes," said Wang. "So we theorized that by inhibiting the enzyme that this gene produces, the 'good guys' -- the tumor-suppressor genes -- would do a better job at destroying cancerous tissue and allowing the body to heal."

To test their theory, Wang and his colleagues treated mice that had cancerous tumors with a molecule to inhibit the PAD4 enzyme. They found that, especially when combined with additional enzyme inhibitors, the treatment worked as effectively as the most-commonly-used chemotherapy drug, doxorubicin, which shrinks tumors by about 70 percent.

Most striking, however, was that the PAD4 enzyme-inhibition strategy caused significantly less damage to healthy tissues. "Current chemotherapy drugs such as doxorubicin don't attack just tumors; unfortunately, they also attack healthy areas of the body," Wang explained. "That's why chemotherapy patients experience such terrible side effects such as weight loss, nausea, and hair loss. Because the PAD4 treatment appears to be less toxic, it could be an excellent alternative to current chemotherapy treatments."

Wang also explained that the PAD4 gene's dual personality -- on the one hand a helpful defense against bacteria, while on the other, a harmful silencer of cancer-suppressor genes -- can be understood from the perspectives of evolution and longer life spans. "Our ancestors didn't have antibiotics, so a bacterial infection could easily result in death, especially in young children," Wang explained. "So, back then, an overactive PAD4 gene was advantageous because the NET bacteria-trapping mechanism was the body's major defense against infection." Wang also explained that on the other hand, because people today have access to antibiotics, we live much longer than our ancestors did. "PAD4's bad effects -- cancer and autoimmune diseases -- tend to be illnesses that appear later in life," Wang said. "So nowadays, an overactive PAD4 gene, while still protective against bacteria, can be detrimental later in life."


Contact: Barbara Kennedy
Penn State

Related medicine news :

1. Governor Rendell Proposes Budget With No Tax Increase, More Money for Public Schools, Strategy for Jobs, Plan to Address Future Deficits
2. SOKO Fitness & Spa Group Broadens Geographic Expansion Strategy
3. Keenan Chief Strategy Officer Selected to Join Editorial Board of Payers & Providers
4. Data Strategy Announces SurePath Services Offering for EMC Avamar
5. New strategy produces promising advance in cancer vaccines
6. New Cancer-Fighting Strategy Focuses On Signaling Molecules
7. Targeting leukemia cells gene addiction presents new strategy for treatment
8. Novel Parkinson's Treatment Strategy Involves Cell Transplantation
9. A new strategy normalizes blood sugars in diabetes
10. Promising strategy for treatment of lung cancer
11. ActiveStrategy iRound™ is Launched to Enable Seamless Capture of Field-Level Performance Management Data
Post Your Comments:
Related Image:
Strategy discovered to activate genes that suppress tumors and inhibit cancer
(Date:12/1/2015)... San Diego, CA (PRWEB) , ... December 01, ... ... simplicity and scale , Visage Imaging Inc. (“Visage”), a wholly owned subsidiary of ... Ease® mobile imaging results enhancements at the Radiological Society of North America (RSNA) ...
(Date:12/1/2015)... ... December 01, 2015 , ... Lutronic, a leading innovator ... the latest addition to the devices for sale in the United States. Clarity ... and long-pulsed 1064 nm Nd:YAG lasers, into a single platform that is easy to ...
(Date:12/1/2015)... ... December 01, 2015 , ... PartnerTech ... through membership and leadership since 2008. Gary Bruce, President of PartnerTech North America, ... has spent a significant amount of time in Sweden since joining PartnerTech based ...
(Date:12/1/2015)... , ... December 01, 2015 , ... ... on receiving the 2015 HSJ Acute Sector Innovation Award on November 18th. This ... patient care experience, and propose exciting enhancements to the medical landscape. , The ...
(Date:11/30/2015)... , ... November 30, 2015 , ... Trevor and Taylor ... as they play for the chance to represent the United States. This hybrid ... to be a part of their journey in addition to offering corporate sponsors with ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... Germany , December 1, 2015 /PRNewswire/ ... leading global manufacturer of eye and gaze tracking solutions, ... SMI remote eye trackers as a component of its ... concussions, eye sight, and medical and performance issues in ... part of SMI,s mass-market-ready eye tracking platform, which is ...
(Date:12/1/2015)... 2015 --> ... Leeuwenhoek Hospital (NKI-AVL), among the world,s largest and ... Gamma Knife® Icon™, the company,s latest generation stereotactic ... --> --> With the option ... Leksell Gamma Knife Icon offers greatly enhanced flexibility ...
(Date:12/1/2015)... Dec. 01, 2015 ... "Drug Delivery Technology Market 2015 - Forecast ... --> ) has announced the addition ... - Forecast to 2020" report to their ... ) has announced the addition of the ...
Breaking Medicine Technology: